ATLASRezera Inc. IPO (RZRA)
The data feed lists Rezera Inc. for NASDAQ with a start date of Nov 12, 2026, status "Expected, not confirmed", and an offer price of $12.00 per the final prospectus (S-1/A).
Updated November 6, 2026 · Source: IPO calendar data feed (EODHD) and the company's SEC filings
What the company does
Rezera Inc. is a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly-owned oral inhibitors of NOD-like receptor protein 3 (NLRP3), based in Boston, MA. Its lead product candidate, ruvonoflast, has been evaluated in five completed human clinical trials and is planned for a Phase 3 trial in peripheral artery disease (PAD) in the first half of 2027. The company also develops trabzanoflast, an NLRP3 inhibitor designed for CNS penetration targeting neuroinflammatory diseases.
The offer
- Offer price
- $12.00
- Shares offered
- 16,666,667
- Over-allotment option
- 2,500,000 shares
- Net proceeds to the company
- $181.0M ($208.9M with full option)
- Shares outstanding after the offering
- 20,776,793
- Lead underwriters
- Jefferies, TD Cowen, Cantor
- Lock-up
- 180 days
Financials
| US$ thousands | FY2024 | FY2025 | 6M 2025 | 6M 2026 |
|---|---|---|---|---|
| Net income (loss) | -25,205 | -42,179 | -13,723 | -25,537 |
| Cash and equivalents | — | — | — | 3,851 |
| Total assets | — | — | — | 9,211 |
Key risks
No approved products. Rezera is a clinical-stage company with no approved products and has not generated any revenue from product sales, relying entirely on financing to fund operations.
No PAD clinical trials yet. To date, Rezera has not conducted clinical trials of ruvonoflast in patients with PAD, its lead planned indication.
Insufficient proceeds for trabzanoflast. At the assumed offering size, the company does not expect the net proceeds of this offering, together with its existing cash and cash equivalents, to be sufficient to fund a Phase 2 proof-of-concept trial of trabzanoflast through topline data.
Accumulated deficit. As of June 30, 2026, Rezera had an accumulated deficit of $210,679 thousand and total stockholders' deficit of $(199,383) thousand.
Lock-up expiry selling pressure. After the lock-up agreements expire 180 days from the date of the prospectus, up to an additional 4,110,126 shares of common stock will be eligible for sale in the public market, which could cause the stock price to fall.
Timeline
- Oct 21, 2026 · Registration statement filed (S-1)
- Nov 5, 2026 · Amendment (S-1/A)
Sources on SEC EDGAR
Facts come from the company's SEC filings; calendar data from EODHD. Information only, not investment advice. Profile updated Nov 6, 2026.
Calendar data
| Status in feed | Expected, not confirmed |
|---|---|
| Start date | Nov 12, 2026 |
| Exchange | NASDAQ |
| Price range | $11 to $13 |
| Shares offered | 16,666,667 |
| Deal size (shares x price) | $216.7M |
| Filing date | Nov 12, 2026 |
| Last amended | Nov 12, 2026 |
Follow this IPO in ATLAS PRO
IPO alerts are part of ATLAS PRO. Create your account to follow RZRA and get one email when it starts trading.
Create an accountFrequently asked questions
What does Rezera Inc. do?
Rezera Inc. is a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly-owned oral inhibitors of NOD-like receptor protein 3 (NLRP3), based in Boston, MA. Its lead product candidate, ruvonoflast, has been evaluated in five completed human clinical trials and is planned for a Phase 3 trial in peripheral artery disease (PAD) in the first half of 2027. The company also develops trabzanoflast, an NLRP3 inhibitor designed for CNS penetration targeting neuroinflammatory diseases.
How much is the Rezera Inc. IPO raising?
The final prospectus sets a price of $12.00 per share for 16,666,667 shares.
Who are the underwriters of the Rezera Inc. IPO?
Jefferies, TD Cowen, Cantor.
When is the Rezera Inc. IPO?
The data feed lists a start date of Nov 12, 2026 with status "Expected, not confirmed". Expected dates are not confirmations and can change.
What is the Rezera Inc. IPO price range?
According to the final prospectus (S-1/A), the offer price is $12.00 per share.
What does "Expected" mean?
The feed lists the deal with a start date but no final pricing yet. Dates can move or the deal can be withdrawn.
Can I get an email when this IPO starts trading?
Yes. ATLAS PRO accounts can follow an IPO inside the platform and get one email when it starts trading. This is information, not investment advice.
Educational information, not investment advice. Disclaimer